These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 11439206)

  • 21. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
    Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
    Dobrowsky W; Naudé J
    Radiother Oncol; 2000 Nov; 57(2):119-24. PubMed ID: 11054514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
    Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
    Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of conventional fractionation (five fractions per week) and altered fractionation (six fractions per week) in stage I and II squamous cell carcinoma of oropharynx: An institutional study.
    Poddar J; Sharma AD; Kunikullaya SU; Neema JP
    Indian J Cancer; 2017; 54(1):6-10. PubMed ID: 29199652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.
    Dische S; Saunders M; Barrett A; Harvey A; Gibson D; Parmar M
    Radiother Oncol; 1997 Aug; 44(2):123-36. PubMed ID: 9288840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
    Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
    Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.
    Awwad HK; Lotayef M; Shouman T; Begg AC; Wilson G; Bentzen SM; Abd El-Moneim H; Eissa S
    Br J Cancer; 2002 Feb; 86(4):517-23. PubMed ID: 11870530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
    Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
    Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions.
    Suwinski R; Bankowska-Wozniak M; Majewski W; Sowa A; Idasiak A; Ziolkowska E; Windorbska W; Tarnawski R; Skladowski K; Maciejewski B
    Radiother Oncol; 2005 Oct; 77(1):58-64. PubMed ID: 16157401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.
    Skladowski K; Maciejewski B; Golen M; Tarnawski R; Slosarek K; Suwinski R; Sygula M; Wygoda A
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):706-13. PubMed ID: 17011446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis.
    Matuschek C; Haussmann J; Bölke E; Gripp S; Schuler PJ; Tamaskovics B; Gerber PA; Djiepmo-Njanang FJ; Kammers K; Plettenberg C; Anooshahr B; Orth K; Budach W
    Radiat Oncol; 2018 Oct; 13(1):195. PubMed ID: 30286777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer.
    Suwiński R; Bańkowska-Woźniak M; Majewski W; Idasiak A; Maciejewski A; Ziółkowska E; Windorbska W; Składowski K; Miszczyk L; Maciejewski B
    Radiother Oncol; 2008 May; 87(2):155-63. PubMed ID: 18342964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity.
    Skladowski K; Maciejewski B; Golen M; Pilecki B; Przeorek W; Tarnawski R
    Radiother Oncol; 2000 May; 55(2):101-10. PubMed ID: 10799721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
    Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
    J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.
    Porceddu SV; Bressel M; Poulsen MG; Stoneley A; Veness MJ; Kenny LM; Wratten C; Corry J; Cooper S; Fogarty GB; Collins M; Collins MK; Macann AMJ; Milross CG; Penniment MG; Liu HY; King MT; Panizza BJ; Rischin D
    J Clin Oncol; 2018 May; 36(13):1275-1283. PubMed ID: 29537906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
    Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
    J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and outcome of a progressively accelerated concomitant boost radiotherapy schedule for head and neck carcinomas.
    Allal AS; Bieri S; Miralbell R; Marchal F; Lehmann W; Kurtz JM
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):685-9. PubMed ID: 9240633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer.
    Leborgne F; Zubizarreta E; Fowler J; Ortega B; Mezzera J; Deus JL; Leborgne JH
    Int J Cancer; 2000 Apr; 90(2):80-91. PubMed ID: 10814958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.
    Pigorsch SU; Wilkens JJ; Kampfer S; Kehl V; Hapfelmeier A; Schläger C; Bier H; Schwaiger M; Combs SE
    Radiat Oncol; 2017 Mar; 12(1):45. PubMed ID: 28249612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.